✦ LIBER ✦

Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study

✍ Scribed by M Colozza; G Bisagni; A.M Mosconi; S Gori; C Boni; R Sabbatini; A Frassoldati; R Passalacqua; A.Rosa Bian; C Rodinò; E Rondini; R Algeri; S Di Sarra; V De Angelis; G Cocconi; M Tonato

Book ID: 117659125
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 191 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)00452-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P86 Epirubicin as a single agent in comp

P86 Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer

✍ M. Colozza; G. Bisagni; A.M. Mosconi; S. Gori; C. Boni; A. Rosa Bian; R. Sabbati 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A randomized trial of CMF versus CMFVP a

A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study

✍ William C. Wood; Raymond B. Weiss; Douglass C. Tormey; James F. Holland; Patrick 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 389 KB

CMF versus goserelin as adjuvant therapy

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)

✍ Gunter von Minckwitz; Erika Graf; Matthias Geberth; Wolfgang Eiermann; Walter Jo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 321 KB

C-ERB-B2 expression as a predictor of ou

C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients

✍ M. Colozza; S. Gori; A.M. Mosconi; E. Bucciarelli; G. Bisagni; C. Rodinò; A.Rosa 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Acute toxicity of concurrent adjuvant ra

Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients: a prospective, comparative, non-randomised study

✍ W.E Fiets; R.P van Helvoirt; J.W.R Nortier; I van der Tweel; H Struikmans 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 214 KB

Her 2 and topoisomerase (TOPO)IIα as pre

Her 2 and topoisomerase (TOPO)IIα as predictive markers for node-positive (N+) breast cancer (BC) patients (PTS) randomised to adjuvant CMF or epirubicin (E) — cyclophosphamide (C)

✍ A. Di Leo; D. Larsimont; M. Beauduin; A. Vindevoghel; J. Michel; S. Dolci; S. Ba 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 265 KB